6533b857fe1ef96bd12b4f13
RESEARCH PRODUCT
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
John BarnardAref Al-kaliVey NorbertEllen K. RitchieMark R. LitzowPau MontesinosUlrich GermingAmer M. ZeidanMikkael A. SekeresThomas CluzeauRami S. KomrokjiJuan BerguaNikolai A. PodoltsevRaphael ItzyksonThomas PrebetJosefina SerranoVivek VermaTae Kon KimPierre FenauxAmir T. FathiSarah PerreaultSteven D. GoreMaximilian StahlValeria SantiniMichelle DeveauxAndrew M. BrunnerGail J. RobozVijaya Raj Bhattsubject
AdultMaleOncologyCancer Researchmedicine.medical_specialtyMyeloidAdolescentendocrine system diseasesmedicine.medical_treatmentHematopoietic stem cell transplantationRisk AssessmentYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTransplantation HomologousneoplasmsSurvival analysisAgedRetrospective StudiesAged 80 and overbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisTransplantationLeukemia Myeloid AcuteLeukemiaTreatment Outcomemedicine.anatomical_structureOncologyTolerabilityHypomethylating agentDrug Resistance Neoplasmhypomethylating agent acute myeloid leukemia.FemaleNeoplasm Recurrence Localbusinessdescription
Patients with primary refractory or relapsed-acute myeloid leukemia (RR-AML), particularly older adults, have dismal outcomes and limited therapy options [1]. Given the tolerability of hypomethylat...
year | journal | country | edition | language |
---|---|---|---|---|
2018-07-02 | Leukemia & Lymphoma |